Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$23.75

-0.32 (-1.33%)

08:09
01/14/19
01/14
08:09
01/14/19
08:09

FDA PDUFA Date for Exelixis for Cabometyx (Cabozantinib) is January 14, 2019

  • 14

    Jan

EXEL Exelixis
$23.75

-0.32 (-1.33%)

10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
Piper Jaffray optimistic on Exelixis' Cabometyx
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $29 price target on Exelixis. The analyst noted that Exelixis initiated a Phase III trial of Cabometyx in radioiodine-refractory differentiated thyroid cancer, or DTC. He is looking for continued Cabometyx adoption in first and second-line renal cell carcinoma with sales of $572M this year, and sees Cabometyx approval in 2nd-line liver cancer by the January 14 PDUFA date, which will help drive sales to $873M in 2019.
11/02/18
NEED
11/02/18
NO CHANGE
Target $30
NEED
Buy
Exelixis well positioned for future I/O combos, says Needham
Needham analyst Chad Messer said cabozantinib is "becoming the drug of choice in second line treatment in RCC" and he believes immuno-oncology combos will support future growth. Exelixis is running several clinical programs investigating cabozantinib in combination with I/O drugs, noted Messer, who keeps a Buy rating and $30 price target on Exelixis following the company's Q3 report.
11/04/18
PIPR
11/04/18
NO CHANGE
Target $26
PIPR
Overweight
Exelixis price target lowered to $26 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Exelixis to $26 from $29, while reiterating an Overweight rating on the shares. The analyst notes the company delivered another beat with U.S. CABOMETYX sales of $158M in Q3. Although I-O is beginning to dominate front-line RCC, Tenthoff believes CABO is competitively positioned in certain patients and with ongoing I-O combo studies of its own. Next, he expects CABOMETYX label expansion in hepatocellular carcinoma with approval by the January 14th PDUFA date. The analyst now forecasts CABOMETYX sales of $595M in 2018, $826M in 2019, peaking at $1.38B in 2024.
11/27/18
PIPR
11/27/18
NO CHANGE
Target $26
PIPR
Overweight
Exelixis's Cabometyx remains competitive positioned, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $26 price target on Exelixis after its management's presentation at the annual Piper Jaffray Healthcare Conference. The analyst notes that its CABOMETYX is the tyrosine kinase inhibitor choice in the 2nd and 3rd line kidney cancer. Tenthoff adds that although immuno-oncology drugs are starting to dominate Renal Cell Carcinoma, CABOMETYX is still "competitively positioned with a better potency and safety profile".

TODAY'S FREE FLY STORIES

SSW

Seaspan

$9.16

0.16 (1.78%)

17:33
01/18/19
01/18
17:33
01/18/19
17:33
Syndicate
Breaking Syndicate news story on Seaspan »

Seaspan files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.38

0.75 (1.54%)

17:30
01/18/19
01/18
17:30
01/18/19
17:30
Hot Stocks
Textron subsidiary awarded $439.56M government contract modification »

Bell Helicopter Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TAC

TransAlta

$4.91

0.04 (0.82%)

17:28
01/18/19
01/18
17:28
01/18/19
17:28
Hot Stocks
Mangrove Partners reports 9.4% passive stake in TransAlta »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$36.27

0.42 (1.17%)

17:27
01/18/19
01/18
17:27
01/18/19
17:27
Hot Stocks
Telephone and Data's Meyers sells 80,465 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change  »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

16:30
01/18/19
01/18
16:30
01/18/19
16:30
Options
Preliminary option volume of 26.9M today »

Preliminary option volume…

NBRV

Nabriva Therapeutics

$1.97

-0.01 (-0.51%)

16:27
01/18/19
01/18
16:27
01/18/19
16:27
Conference/Events
Nabriva Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Apr

VLRS

Volaris

$7.50

0.04 (0.54%)

16:21
01/18/19
01/18
16:21
01/18/19
16:21
Conference/Events
International Aviation Club to host monthly luncheon meeting »

Enrique Beltranena, CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
01/18/19
01/18
16:20
01/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/18/19
01/18
16:17
01/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/18/19
01/18
16:16
01/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$14.48

-0.57 (-3.79%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
Conference/Events
Forty Seven to hold KOL breakfast symposium »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$302.26

-45.18 (-13.00%)

, WMT

Walmart

$97.75

1.01 (1.04%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks opened higher and…

TSLA

Tesla

$302.26

-45.18 (-13.00%)

WMT

Walmart

$97.75

1.01 (1.04%)

CVS

CVS Health

$65.49

2.13 (3.36%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

FB

Facebook

$150.01

1.77 (1.19%)

AAPL

Apple

$156.85

0.99 (0.64%)

QCOM

Qualcomm

$55.26

0.44 (0.80%)

FND

Floor & Decor

$31.99

2.34 (7.89%)

OZK

Bank OZK

$32.07

4.47 (16.20%)

VFC

VF Corp.

$82.39

9.135 (12.47%)

NLS

Nautilus

$7.00

-4.76 (-40.48%)

CASA

Casa Systems

$11.23

-3.17 (-22.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

SNE

Sony

$50.08

0.58 (1.17%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Periodicals
Sony Music ends working relationship with R. Kelly, Variety reports »

Sony Music has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$64.58

0.53 (0.83%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Hot Stocks
Prologis, Ivanhoe Cambridge form $880M joint venture in Brazil »

Prologis and Ivanhoe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CYDY

CytoDyn

$0.00

(0.00%)

16:10
01/18/19
01/18
16:10
01/18/19
16:10
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHF

WhiteHorse Finance

$13.58

-0.105 (-0.77%)

16:09
01/18/19
01/18
16:09
01/18/19
16:09
Hot Stocks
WhiteHorse Finance, STRS Ohio form JV to invest in debt facilities »

WhiteHorse Finance, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.